Plus Therapeutics, Inc. (Nasdaq: PSTV) , a clinical-stage pharmaceutical company developing novel, targeted radiotherapeutics for rare and difficult-to-treat cancers,  announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track designation for Rhenium-186 NanoLiposome (¹⁸⁶RNL) for the treatment of leptomeningeal metastases (LM), a rare complication in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord, affecting nearly 5% of people living with cancer. The Company recently announced clearance of its Investigational New Drug (IND) application from the FDA, and expects to initiate patient accrual in the ReSPECT-LM Phase 1 dose escalation clinical trial of ¹⁸⁶RNL in the fourth quarter of 2021.

To read more please visit:

PLUS THERAPEUTICS Receives FDA Fast Track Designation for 186RNL Targeted  Radiotherapeutic  for Leptomeningeal Metastases

Source: PLUS THERAPEUTICS